secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2022-03-16T23:59:59+00:00
Accession:  0001193125-22-077358
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Amneal EVP & Chief Commercial Officer–Specialty Joseph Todisco to depart by May 15, 2022
--------------------------------------------------------------------------------

- Joseph Todisco is stepping down from his role as EVP, Chief Commercial Officer – Specialty.
- He will remain through a transition period expected to end May 15, 2022.
- Todisco is leaving to pursue an opportunity outside the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000119312522077358/0001193125-22-077358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000119312522077358/d294673d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-077358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer